
Milestone Pharmaceuticals MIST
$ 1.96
-3.22%
Annual report 2025
added 03-20-2026
Milestone Pharmaceuticals Interest Expense 2011-2026 | MIST
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Milestone Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.55 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.55 M | 2.55 M | 2.55 M |
Quarterly Interest Expense Milestone Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 872 K | - | 841 K | 820 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 872 K | 820 K | 844 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 97.64 | 2.24 % | $ 27.2 B | ||
|
Aligos Therapeutics
ALGS
|
2.2 M | $ 8.49 | 6.25 % | $ 83.9 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.63 | -2.42 % | $ 8.73 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | $ 2.18 | 0.46 % | $ 453 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 20.93 | 2.75 % | $ 978 M | ||
|
GT Biopharma
GTBP
|
156 K | $ 0.37 | -0.24 % | $ 2.04 M | ||
|
Halozyme Therapeutics
HALO
|
21.5 M | $ 66.3 | -2.24 % | $ 7.95 B | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Harmony Biosciences Holdings
HRMY
|
-680 K | $ 28.79 | -0.35 % | $ 1.66 B | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
58 K | $ 1.43 | 2.14 % | $ 368 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 3.0 | 2.74 % | $ 4.94 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.17 | 2.08 % | $ 446 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 24.01 | -0.83 % | $ 3.05 B | ||
|
Incyte Corporation
INCY
|
25.1 M | $ 94.32 | -1.82 % | $ 18.4 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 32.28 | 0.12 % | $ 2.14 B | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.47 | -1.34 % | $ 391 M | ||
|
Cidara Therapeutics
CDTX
|
5.81 M | - | - | $ 1.41 B | ||
|
Innate Pharma S.A.
IPHA
|
440 K | $ 1.48 | 4.61 % | $ 235 M | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.57 | 0.78 % | $ 16.1 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B |